Innate Pharma - ADR Forecast, price target & analysts
Innate Pharma - ADR Target price 2025 - Analyst rating & recommendation
Innate Pharma - ADR Classifications & Recommendation:
Innate Pharma - ADR Price Target
| Target Price | $6.81 |
| Price | $1.85 |
| Potential |
268.34%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Innate Pharma - ADR 2026 .
The average Innate Pharma - ADR target price is $6.81.
This is
268.34%
register free of charge
$10.34
458.79%
register free of charge
$2.95
59.33%
register free of charge
|
|
| A rating was issued by 11 analysts: 8 Analysts recommend Innate Pharma - ADR to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Innate Pharma - ADR stock has an average upside potential 2026 of
268.34%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 14.79 | 73.07 |
| 75.69% | 394.03% | |
| EBITDA Margin | -392.90% | 16.18% |
| 2,591.46% | 104.12% | |
| Net Margin | -392.02% | 11.95% |
| 2,588.46% | 103.05% |
6 Analysts have issued a sales forecast Innate Pharma - ADR 2025 . The average Innate Pharma - ADR sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Innate Pharma - ADR EBITDA forecast 2025. The average Innate Pharma - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Innate Pharma - ADR Analysts have issued a net profit forecast 2025. The average Innate Pharma - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.71 | 0.10 |
| 545.45% | 114.08% | |
| P/E | 17.76 | |
| EV/Sales | 2.27 |
7 Analysts have issued a Innate Pharma - ADR forecast for earnings per share. The average Innate Pharma - ADR EPS is
This results in the following potential growth metrics and future valuations:
Innate Pharma - ADR...
Current Innate Pharma - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Dec 08 2024 |
| BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Mar 27 2025 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Dec 08 2024 |
|
Locked
BRYAN GARNIER:
Locked
➜
Locked
|
Nov 12 2024 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Nov 12 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
